Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
Ocular Therapeutix (NASDAQ: OCUL) has announced it will host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss its fourth quarter and full year 2024 financial results and recent business developments. The company, which focuses on redefining the retina experience, will provide access to the event through both U.S. (1-877-407-9039) and International (1-201-689-8470) dial-in numbers. The webcast will be available live and archived on the company's Investor Relations page for at least 30 days following the presentation.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato che ospiterà una conferenza telefonica e un webcast il lunedì 3 marzo 2025, alle 8:00 AM ET per discutere i risultati finanziari del quarto trimestre e dell'intero anno 2024, oltre agli sviluppi recenti dell'azienda. La società, che si concentra sulla ridefinizione dell'esperienza retinica, fornirà accesso all'evento tramite numeri di contatto sia per gli Stati Uniti (1-877-407-9039) che per l'Internazionale (1-201-689-8470). Il webcast sarà disponibile in diretta e archiviato nella pagina delle Relazioni con gli Investitori dell'azienda per almeno 30 giorni dopo la presentazione.
Ocular Therapeutix (NASDAQ: OCUL) ha anunciado que llevará a cabo una conferencia telefónica y un webcast el lunes 3 de marzo de 2025, a las 8:00 AM ET para discutir sus resultados financieros del cuarto trimestre y del año completo 2024, así como los recientes desarrollos comerciales. La empresa, que se centra en redefinir la experiencia de la retina, proporcionará acceso al evento a través de números de marcación tanto para EE. UU. (1-877-407-9039) como para Internacional (1-201-689-8470). El webcast estará disponible en vivo y archivado en la página de Relaciones con Inversores de la empresa durante al menos 30 días después de la presentación.
Ocular Therapeutix (NASDAQ: OCUL)는 2025년 3월 3일 월요일 오전 8시 ET에 2024년 4분기 및 연간 재무 결과와 최근 비즈니스 개발에 대해 논의하기 위해 전화 회의 및 웹캐스트를 개최한다고 발표했습니다. 망막 경험을 재정의하는 데 중점을 두고 있는 이 회사는 미국 (1-877-407-9039) 및 국제 (1-201-689-8470) 전화번호를 통해 이벤트에 대한 접근을 제공합니다. 웹캐스트는 생중계되며 발표 후 최소 30일 동안 회사의 투자자 관계 페이지에서 아카이브로 제공됩니다.
Ocular Therapeutix (NASDAQ: OCUL) a annoncé qu'elle organisera une conférence téléphonique et un webinaire le lundi 3 mars 2025, à 8h00 ET pour discuter de ses résultats financiers du quatrième trimestre et de l'année complète 2024, ainsi que des récents développements commerciaux. L'entreprise, qui se concentre sur la redéfinition de l'expérience rétinienne, fournira un accès à l'événement via des numéros de composition pour les États-Unis (1-877-407-9039) et pour l'international (1-201-689-8470). Le webinaire sera disponible en direct et archivé sur la page des relations investisseurs de l'entreprise pendant au moins 30 jours après la présentation.
Ocular Therapeutix (NASDAQ: OCUL) hat angekündigt, dass am Montag, den 3. März 2025, um 8:00 Uhr ET eine Telefonkonferenz und ein Webcast stattfinden werden, um die Finanzzahlen des vierten Quartals und des gesamten Jahres 2024 sowie aktuelle Geschäftsentwicklungen zu besprechen. Das Unternehmen, das sich auf die Neugestaltung des Retina-Erlebnisses konzentriert, wird den Zugang zu der Veranstaltung über sowohl US-(1-877-407-9039) als auch internationale (1-201-689-8470) Einwahlnummern bereitstellen. Der Webcast wird live verfügbar sein und mindestens 30 Tage nach der Präsentation auf der Investor-Relations-Seite des Unternehmens archiviert werden.
- None.
- None.
BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024.
Conference Call and Webcast Information:
Date: Monday, March 3, 2025, at 8:00 AM ET
Participant Dial-In (U.S.): 1 (877) 407-9039
Participant Dial-in (International): 1 (201) 689-8470
Conference ID: 13750940
Webcast Access: Please click here
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When will Ocular Therapeutix (OCUL) report Q4 and full year 2024 earnings?
How can investors access OCUL's Q4 2024 earnings call?
How long will OCUL's Q4 2024 earnings webcast be available for replay?
What is the conference ID for OCUL's Q4 2024 earnings call?
